← uniQure N.V. (QURE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
uniQure N.V. (QURE)
Pharmaceutical Preparations · market cap $2.7B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
uniQure N.V. (QURE) is a gene therapy company with 209 employees and a ~$2.6B market cap, trading at ~$41.10. Its most consequential near-term event is a PDUFA date for its Huntington's disease gene therapy expected February 12, 2027, with a BLA filing targeted by September 30, 2026. The company also carries a Phase 2 pipeline in Fabry disease (AMT-191), Sanfilippo Syndrome B (rAAV2/5-hNAGLU), and ALS (AMT-162).
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-02-12 (est.)PDUFA · uniQure Huntington's disease gene therapyimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AMT-191 | Phase 2 | Fabry Disease |
| rAAV2/5-hNAGLU | Phase 2 | Sanfilippo Syndrome B |
| AMT-162 | Phase 2 | Amyotrophic Lateral Sclerosis |
Price & technical context
3-month
-44.1%
6-month
+38.4%
12-month
-60.0%
52-wk range
$9.03–$70.59
vs 50-day MA
-46.3%
vs 200-day MA
-21.3%
Realized vol
145.0%
Max drawdown
-87.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for QURE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.